TMCnet News
Research and Markets: Leukemia Drug Pipeline Update 2015 - 318 Companies Plus Partners Developing 416 Leukemia Drugs in 668 Developmental ProjectsResearch and Markets (http://www.researchandmarkets.com/research/grr3bw/leukemia_drug) has announced the addition of the "Leukemia Drug Pipeline Update 2015" report to their offering. Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today 318 companies plus partners developing 416 leukemia drugs in 668 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 157 rugs. Leukemia Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 297 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 283 out of the 288 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 66 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath. Pipeline Breakdown According to Number of Drugs
Delivery Format: Desktop App plus Online Access to Updates (One Year) For more information visit http://www.researchandmarkets.com/research/grr3bw/leukemia_drug
|
